Neoadjuvant Palbociclib Plus Giredestrant or Anastrozole for ER-Positive, HER2-Negative, Early Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study
Lancet Oncol 2023 Sep 01;24(9)1029-1041, SA Hurvitz, A Bardia, V Quiroga, YH Park, I Blancas, JL Alonso-Romero, A Vasiliev, H Adamchuk, M Salgado, DA Yardley, O Berzoy, P Zamora-Auñón, D Chan, G Spera, C Xue, E Ferreira, T Badovinac Crnjevic, PD Pérez-Moreno, V López-Valverde, J Steinseifer, TM Fernando, HM Moore, PA FaschingFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.